ORPN vs. QLGN, AGRX, SBFM, SXTP, CYCC, HSTO, EVOK, CMRA, DRMA, and BDRX
Should you be buying Bioblast Pharma stock or one of its competitors? The main competitors of Bioblast Pharma include Qualigen Therapeutics (QLGN), Agile Therapeutics (AGRX), Sunshine Biopharma (SBFM), 60 Degrees Pharmaceuticals (SXTP), Cyclacel Pharmaceuticals (CYCC), Histogen (HSTO), Evoke Pharma (EVOK), Comera Life Sciences (CMRA), Dermata Therapeutics (DRMA), and Biodexa Pharmaceuticals (BDRX). These companies are all part of the "medical" sector.
Bioblast Pharma (NASDAQ:ORPN) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking and earnings.
Bioblast Pharma has a net margin of 0.00% compared to Qualigen Therapeutics' net margin of -233.25%. Bioblast Pharma's return on equity of 0.00% beat Qualigen Therapeutics' return on equity.
Bioblast Pharma has higher earnings, but lower revenue than Qualigen Therapeutics.
In the previous week, Qualigen Therapeutics had 1 more articles in the media than Bioblast Pharma. MarketBeat recorded 1 mentions for Qualigen Therapeutics and 0 mentions for Bioblast Pharma. Qualigen Therapeutics' average media sentiment score of 1.89 beat Bioblast Pharma's score of 0.00 indicating that Qualigen Therapeutics is being referred to more favorably in the news media.
Bioblast Pharma has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of -0.79, meaning that its stock price is 179% less volatile than the S&P 500.
4.5% of Bioblast Pharma shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 5.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Bioblast Pharma received 205 more outperform votes than Qualigen Therapeutics when rated by MarketBeat users. However, 87.50% of users gave Qualigen Therapeutics an outperform vote while only 78.23% of users gave Bioblast Pharma an outperform vote.
Summary
Bioblast Pharma beats Qualigen Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Bioblast Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Bioblast Pharma Competitors List
Related Companies and Tools